title: Computer-based assessment of cognitive functions in brain tumor patients.
abstract: NeuroCogFX is a short yet comprehensive computer-based neuropsychological battery of tests developed to investigate neurological patients for cognitive dysfunction after potentially neurotoxic therapy. NeuroCogFX had been standardized in a group of 242 healthy controls (Fliessbach et al., Fortschr Neurol Psychiatr 74:643-650, 2006). The present study was conducted to assess the practicability, reliability, and validity of NeuroCogFX in brain tumor patients without active disease after tumor-directed therapy. To evaluate its validity, neuropsychological testing with NeuroCogFX was completed parallel to a battery of established neuropsychological tests in 54 patients with different types of brain tumors and without active disease for at least 6 months. Retest reliability was assessed in a different sample of 49 patients with gliomas. Results showed good practicability with a median test duration of 28 min (range 16-51 min). Most subtests showed medium-sized retest reliability in healthy controls and tumor patients, with the exception of the 2-back test and reaction time measures in tumor patients. Convergent validity was confirmed for the domains psychomotor speed, verbal memory, and verbal short-term memory. NeuroCogFX enables serial scientific neuropsychological assessment of brain tumor patients. It can be carried out within a short period of time by non-academic personnel and is therefore applicable to large cohorts, e.g., within clinical trials.
authors.affiliation: Department of Epileptology, University of Bonn, Bonn, Germany.
authors.forename: Klaus
authors.initials: K
authors.lastname: Fliessbach
authors.forename: Sabine
authors.initials: S
authors.lastname: Rogowski
authors.forename: Christian
authors.initials: C
authors.lastname: Hoppe
authors.forename: Michael
authors.initials: M
authors.lastname: Sabel
authors.forename: Mathias
authors.initials: M
authors.lastname: Goeppert
authors.forename: Christoph
authors.initials: C
authors.lastname: Helmstaedter
authors.forename: Pasquale
authors.initials: P
authors.lastname: Calabrese
authors.forename: Gabriele
authors.initials: G
authors.lastname: Schackert
authors.forename: Joerg-Christian
authors.initials: JC
authors.lastname: Tonn
authors.forename: Matthias
authors.initials: M
authors.lastname: Simon
authors.forename: Uwe
authors.initials: U
authors.lastname: Schlegel
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000145:classification / Q000150:complications*; D003072:Cognition Disorders / Q000175:diagnosis* / Q000209:etiology*; D003936:Diagnosis, Computer-Assisted / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination; D009483:Neuropsychological Tests; D025341:Principal Component Analysis; D012016:Reference Values; D015203:Reproducibility of Results; D055815:Young Adult
references.citation: Semin Oncol. 2003 Dec;30(6 Suppl 19):45-8
references.pmid: 14765385
references.citation: Fortschr Neurol Psychiatr. 2006 Nov;74(11):643-50
references.pmid: 17103364
references.citation: Radiother Oncol. 1996 Oct;41(1):55-9
references.pmid: 8961368
references.citation: Neurology. 2002 Jul 9;59(1):121-3
references.pmid: 12105319
references.citation: J Clin Oncol. 1994 Mar;12(3):627-42
references.pmid: 8120563
references.citation: Neuropsychol Rev. 1995 Sep;5(3):203-21
references.pmid: 8653109
references.citation: Cancer. 1994 Nov 15;74(10):2828-35
references.pmid: 7954244
references.citation: Neurology. 2005 Apr 12;64(7):1184-8
references.pmid: 15824344
references.citation: J Clin Oncol. 1998 Jun;16(6):2195-201
references.pmid: 9626221
references.citation: Neurology. 2004 Feb 24;62(4):548-55
references.pmid: 14981169
references.citation: Epilepsy Behav. 2009 Oct;16(2):298-310
references.pmid: 19733124
references.citation: J Neurooncol. 2007 Jan;81(2):175-84
references.pmid: 16850104
references.citation: J Neurooncol. 1999 Jul;43(3):277-86
references.pmid: 10563434
references.citation: J Clin Oncol. 2003 Jul 1;21(13):2519-24
references.pmid: 12829670
references.citation: Lancet. 2002 Nov 2;360(9343):1361-8
references.pmid: 12423981
references.citation: Neurology. 2001 May 22;56(10):1285-90
references.pmid: 11376174
references.citation: J Clin Oncol. 1998 Mar;16(3):859-63
references.pmid: 9508166
references.citation: Lancet Neurol. 2004 Mar;3(3):159-68
references.pmid: 14980531
references.citation: Recent Results Cancer Res. 2009;171:165-74
references.pmid: 19322544
references.citation: Ann Oncol. 2007 Jul;18(7):1145-51
references.pmid: 17284616